Stevanato Group

Activities: Pharmaceutical

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries. Stevanato Group delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle at each of the development, clinical, and commercial stages.
Stevanato Group counts more than 5,600 people in 16 sites in 9 countries.

Visit website

Profile

Advanced Drug Containment Solutions & Analytical Services

Stevanato Group boasts unique expertise in providing advanced pharmaceutical containers from glass tubing. Its comprehensive portfolio covers every customer need, from those related to small molecules to highly sensitive drugs. Stevanato Group produces vials, syringes, and cartridges for different applications, such as vaccines, diabetes care, anesthetics, hormones, anticoagulants, and biologics. Glass containers are available both in bulk and in EZ-fill®, the market-recognized ready-to-use configuration. Stevanato Group can also provide container closure and device characterization analytical services through its Technology Excellence Centers.

Stevanato Group

Vision Inspection, Assembly & Packaging Technologies: A Modular & Flexible Approach

Stevanato Group's capabilities range from modular assembly platforms and packaging lines to advanced vision inspection machines, including manual, semi-automatic, and automatic. Stevanato Group equipment can inspect a wide range of liquid, emulsions, viscous, gel-like, powder, and lyophilized drugs, catering to the needs of both small firms and big pharma companies producing blockbuster drugs.

Trending Articles

  1. Catalent Boston adds to oral spray drying capacity to support late-stage clinical trials and commercialisation Catalent, the leading provider of oral drug development solutions, bioavailability enhancing technologies and flexible manufacturing, has completed a series of upgrades to its...
  2. £20m Scottish oligonucleotide manufacturing innovation centre now under construction The centre will act as an innovation centre, assisting in the development and optimisation of oligonucleotide manufacturing processes, while also bolstering the UK's...
  3. Novo Nordisk invests DKK 8.5bn into new Danish modular production site This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within...
  4. Scinai Immunotherapeutics establishes Delaware-based US CDMO subsidiary The biopharmaceutical company now operates contract development and manufacturing services in both Jerusalem and Delaware
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

Related Content

Packaging

Nipro launches D2F Glass Vials powered by Stevanato Group's EZ-fill Technology

Nipro PharmaPackaging, a global leader in glass tubing, glass primary packaging, and medical devices, is proud to announce the launch of its innovative D2F (Direct-to-Fill) glass vials
Manufacturing

SCHOTT, Gerresheimer and Stevanato Group form the 'Alliance for RTU'

The scheme will promote the adoption of ready-to-use (RTU) vials and cartridges for CDMOs in the injectable scene
Manufacturing

Quantoom collaborates with Stevanato to elevate mRNA production

The two companies have entered into a collaboration to promote and democratise access to mRNA production technologies worldwide by launching Quantoom's Nfinity platform
Distribution

DWK enters into distribution agreement with drug containment specialist Stevanato

The collaboration will leverage DWK Life Sciences experience in supplying a global network of laboratories and biopharma customers to broaden the distribution of RTU products
Drug Delivery

Expanding capacity through collaboration

Michael Earl, Director of Pharmaceutical Services at Owen Mumford, and Steven Kaufman, Vice President for Drug Delivery Systems, Stevanato Group, talk to Dr Kevin Robinson about their new partnership
Manufacturing

Industry first experiments break the mould for the VHP decontamination of RTU vials

Markus Heinz, Product Manager, Vial Liquid and Powder at Syntegon, and Fabio Bertacchini, Product Management Director at Stevanato Group, present new possibilities for small batch manufacturing
Distribution

Manufacturing Chemist LIVE 2022 in review (part II)

Taking a front row seat during the two-day pharmaceutical conference in Birmingham, UK, Dr Kevin Robinson reports on what’s new, emerging and exciting in the world of drug delivery and beyond
Subscribe now